ArticleJournal of gastrointestinal oncology2025
Comparison analysis of different doses bevacizumab plus ICIs and interventional therapy in unresectable hepatocellular carcinoma: a real-world study.
Article in Journal of gastrointestinal oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bevacizumab, immune checkpoint inhibitors (ICIs), interventional therapy, either alone or in combination, have demonstrated promising anti-tumor activities in unresectable hepatocellular carcinoma (HCC). However, the optimal dosing strategy for bevacizumab within combination regimens remains undetermined. This study aimed to compare the efficacy and safety of different bevacizumab doses in triple therapy combining bevacizumab, ICIs, and interventional therapy for unresectable HCC. Methods: A retrospective study included patients with unresectable HCC treated with interventional therapy combined with bevacizumab (full dose or half dose) and ICIs between December 2020 and July 2023 was conducted. Propensity score matching (PSM, 1:1) was applied to minimize confounding effects. The progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR) were compared and evaluated. Treatment-related adverse events (AEs) were analyzed to assess safety. Results: Among 66 enrolled patients, 36 received full-dose bevacizumab, and 30 received half-dose bevacizumab. The full-dose group exhibited significantly longer PFS compared to the half-dose group (median PFS: not attained Conclusions: Although full-dose bevacizumab in triple therapy showed prolonged PFS compared to half-dose group, no statistically significant differences were observed in long-term survival outcomes or treatment-related AEs between the two groups. For unresectable HCC patients with severe liver cirrhosis, half-dose bevacizumab may serve as a safer alternative without compromising survival benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.